ABSTRACT
This paper shows the results of associating tricyclic and MAOI antidepressants in the treatment of resistant major depression. Forty five patients from private practice with diagnosis of major depression according to DSM III R criteria, with negative response to separate tricyclic or MAOI treatment, were given both types associated. They improved without dangerous side effects.
Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Depressive Disorder/drug therapy , Monoamine Oxidase Inhibitors/therapeutic use , Adult , Depressive Disorder/diagnosis , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Psychiatric Status Rating ScalesABSTRACT
The incidence of coenzyme Q 10 and its alterations in psychiatrical pathology is studied. A screening of a randomly selected 113-patient sample showed a high percentage of deficiencies: When taken care of, an improvement in patients' clinical pictures, with no secondary complaint could be observed. Results do not yield alteration specificity according to diagnosis. In those cases where values higher than admitted as normal were detected, neither a common symptoms nor the predomination of a determined pathology could be found.
Subject(s)
Mental Disorders/blood , Ubiquinone/blood , Adolescent , Adult , Aged , Aged, 80 and over , Chromatography, High Pressure Liquid , Female , Humans , Male , Middle AgedABSTRACT
This paper shows the results of associating tricyclic and MAOI antidepressants in the treatment of resistant major depression. Forty five patients from private practice with diagnosis of major depression according to DSM III R criteria, with negative response to separate tricyclic or MAOI treatment, were given both types associated. They improved without dangerous side effects.
ABSTRACT
The incidence of coenzyme Q 10 and its alterations in psychiatrical pathology is studied. A screening of a randomly selected 113-patient sample showed a high percentage of deficiencies: When taken care of, an improvement in patients clinical pictures, with no secondary complaint could be observed. Results do not yield alteration specificity according to diagnosis. In those cases where values higher than admitted as normal were detected, neither a common symptoms nor the predomination of a determined pathology could be found.
ABSTRACT
This paper shows the results of associating tricyclic and MAOI antidepressants in the treatment of resistant major depression. Forty five patients from private practice with diagnosis of major depression according to DSM III R criteria, with negative response to separate tricyclic or MAOI treatment, were given both types associated. They improved without dangerous side effects.
Subject(s)
Adjustment Disorders/diagnosis , Depression/diagnosis , Depressive Disorder/diagnosis , Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle AgedABSTRACT
This work is based upon the study of 472 cases from author's private practice. We considered the three following starting points: a) Catecholaminic hypothesis of depressive disorders such as formulated by late Prof. E. Fischer. b) Biochemical analysis of neuro transmitters according to H. Spatz and Mattock to study clinical and laboratory correlation and guide therapy. c) Biological psychiatry's practice and experience in our empirical definition of a final metabolic response to the patients situation. We would like to stress the following conclusions resulting from this investigation: first, the efficacy without unwanted side effects of the formula described as treatment B in the special paragraph; second, a stronger response to tricyclics or Maois when the formula is also administered; third, the confirmation of previous reports pointing out low PEA urinary elimination in those patients with clinical diagnoses different from endogenous depression.
Subject(s)
Catecholamines/urine , Depressive Disorder/metabolism , Neurotransmitter Agents/metabolism , Adjustment Disorders/drug therapy , Adolescent , Adult , Aged , Aniline Compounds/therapeutic use , Antidepressive Agents/therapeutic use , Child , Depressive Disorder/drug therapy , Depressive Disorder/urine , Epoxy Compounds/therapeutic use , Female , Humans , Imipramine/therapeutic use , Male , Middle Aged , Monoamine Oxidase Inhibitors/therapeutic use , Mood Disorders/drug therapy , Neurotic Disorders/drug therapyABSTRACT
This work is based upon the study of 472 cases from authors private practice. We considered the three following starting points: a) Catecholaminic hypothesis of depressive disorders such as formulated by late Prof. E. Fischer. b) Biochemical analysis of neuro transmitters according to H. Spatz and Mattock to study clinical and laboratory correlation and guide therapy. c) Biological psychiatrys practice and experience in our empirical definition of a final metabolic response to the patients situation. We would like to stress the following conclusions resulting from this investigation: first, the efficacy without unwanted side effects of the formula described as treatment B in the special paragraph; second, a stronger response to tricyclics or Maois when the formula is also administered; third, the confirmation of previous reports pointing out low PEA urinary elimination in those patients with clinical diagnoses different from endogenous depression.
